Novo Nordisk announced on Tuesday that it is making a higher-dose version of its popular weight-loss medication, Wegovy, available across the United States.
The new 7.2-milligram dose, branded as Wegovy HD, was recently approved under the FDA Commissioner’s National Priority Review Voucher program last month, marking a significant development in obesity treatment options.
Before this approval, the maximum authorized dose for Wegovy used for weight management was 2.4 mg, making this launch the highest-strength version available to patients.
Wegovy availability and pricing details
Novo Nordisk confirmed that the higher-dose Wegovy will be accessible through US pharmacies, NovoCare Pharmacy, and select telehealth providers.
For adults paying out-of-pocket, the cost is approximately $399 per month.
However, commercially insured patients may benefit from the Wegovy savings offer, which can reduce monthly costs to as low as $25.
The company also plans to introduce a discounted subscription plan for US patients covering their own treatment costs.
In a trial involving adults with obesity but without diabetes, patients taking a 7.2 mg dose lost an average of 21% of body weight, compared with about 18% for the previously highest 2.4 mg dose.
The US Food and Drug Administration granted accelerated approval, while European regulators have also cleared higher dosing, supporting Novo Nordisk’s strategy to strengthen its position in the obesity drug market.
This strategy aims to regain market share lost to Eli Lilly in the obesity-drug sector, reflecting the intensifying competition between major pharmaceutical companies in weight-management therapies.
US market declines amid Iran tensions
US stocks opened lower on Tuesday as a deadline set by former President Donald Trump for Iran to reopen the Strait of Hormuz approached, with expectations of a near-term agreement fading.
The Dow Jones Industrial Average was down 214 points, or 0.46%, while the S&P 500 index fell 0.42% and the Nasdaq 100 declined 0.47%
According to The Wall Street Journal, negotiators are not optimistic about reaching a deal between the US and Iran before the deadline.
Trump reiterated on Monday that the US could target Iran’s infrastructure, including power plants and bridges, if the strait is not reopened by 8 pm ET on Tuesday.
He added that the deadline had been extended by a day due to timing concerns around Easter.
“They have ’til tomorrow,” Trump said, noting that negotiations appear to be ongoing and involve several countries.
Novo Nordisk’s move comes as demand for obesity treatments continues to grow, and competition from Eli Lilly and other pharmaceutical companies intensifies.
At the same time, geopolitical tensions are keeping investors cautious, contributing to volatility in US markets.
With Wegovy HD, Novo Nordisk is offering patients the highest-dose formulation yet, potentially improving weight-loss outcomes while expanding its presence in a competitive market.
The post Can Wegovy HD 7.2 mg drive Novo Nordisk’s obesity drug rebound? appeared first on Invezz
